Achieving clinical remission in severe asthma: What’s new in Asian population?
14 Feb 2025
byProf. Ian Pavord, University of Oxford, UK; Dr. Ken Chan, Chinese University of Hong Kong
Associated eosinophilic inflammation, plays a crucial role in the pathogenesis of severe asthma, current standard-of-care management may not adequately address this important pathogenic contributor. At the 28th Congress of the Asian Pacific Society of Respirology, Professor Ian Pavord from the University of Oxford, UK, discussed how early treatment of underlying inflammation in asthma with biologics, such as the anti–IL-5 biologic mepolizumab, may facilitate clinical remission and improve patient outcomes, especially in the Asian population. Dr Ken Chan from the Chinese University of Hong Kong highlighted the unique characteristics of Asian asthma patients and emphasized the importance of phenotyping in guiding use of biologics.
